Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.46 |
| ▸ | MLNR | O43193 | 1/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CTSD | P07339 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5914806 | 1.00 | SPPL2A (0.46) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL6102011 | 0.91 | SPPL2A (0.45) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL8368997 | 0.89 | SPPL2A (0.49) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL4971126 | 0.89 | SPPL2A (0.51) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL14189510 | 0.89 | SPPL2A (0.49) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL7164090 | 0.89 | SPPL2A (0.49) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL6101693 | 0.89 | MLNR (0.47) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL14189509 | 0.89 | SPPL2A (0.47) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL14189497 | 0.89 | SPPL2A (0.48) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL5928232 | 0.88 | SPPL2A (0.46) | SPPL2AMLNRABCB11LMNACTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020111368-A1 | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | GETMAN DANIEL P (US) | 2002-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111368-A1 | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | DNPEP, PREP, ANPEP | SPPL2A 268/4885MLNR 2955/4885ABCB11 3167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.